rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Enveric Biosciences, Inc.

ENVB · Nasdaq

Health CareBiotechnologyNot moving yet

ENVB stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 26.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
22 (+11)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders22+11 on the quarter
New · exited12 · 1
Reported value$698K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Sio Capital Management, LLCnew · filed 14 Aug 2026180,000$248K+180,000
Ikarian Capital, LLCnew · filed 14 Aug 2026100,002$138K+100,002
AdvisorShares Investments LLCadded · filed 11 Aug 202635,417$49K+18,443+108.7%
RENAISSANCE TECHNOLOGIES LLCnew · filed 13 Aug 202632,058$44K+32,058
ARMISTICE CAPITAL, LLCnew · filed 14 Aug 202632,000$44K+32,000
BOOTHBAY FUND MANAGEMENT, LLCnew · filed 14 Aug 202630,142$42K+30,142
XTX Topco Ltdnew · filed 14 Aug 202618,990$26K+18,990
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 202614,912$21K+14,912
CITADEL ADVISORS LLCnew · filed 14 Aug 202613,965$19K+13,965
StoneX Group Inc.new · filed 12 Aug 202611,814$22K+11,814
31 Dec 2025 – 30 Jun 2026
111722Dec 25Mar 26Jun 26

Everyone who traded it

Frank Pasqualone Company insiderDirector · last 1 Jun 20261 · 0
George A. Kegler Company insiderDirector · last 1 Jun 20260 · 0
Joseph Edward Tucker Company insiderChief Executive Officer · last 1 Jun 20260 · 0
Kevin Michael Coveney Company insiderChief Financial Officer · last 1 Jun 20260 · 0
Marcus Schabacker Company insiderDirector · last 1 Jun 20260 · 0
Michael D. Webb Company insiderDirector · last 1 Jun 20260 · 0
Peter J. Facchini Company insiderChief Innovation Officer · last 1 Jun 20260 · 0
Sheila DeWitt Company insiderDirector · last 1 Jun 20260 · 0
Avani Kanubaddi Company insiderPresident and COO · last 25 Jan 20230 · 0
Jillian Marie Hagel Company insiderVice President of Innovation · last 25 Jan 20230 · 0
Carter Julian Ward Company insiderChief Financial Officer · last 19 Jan 20220 · 0
Bradley George Thompson Company insiderDirector · last 16 Sep 20210 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 24 Mar 202677.8%

Analyst forecasts

No analyst forecasts yet.